Cetera Investment Advisers Lowers Stock Holdings in iShares Biotechnology ETF $IBB

Cetera Investment Advisers cut its holdings in iShares Biotechnology ETF (NASDAQ:IBB) by 2.3% in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 61,454 shares of the financial services provider’s stock after selling 1,467 shares during the period. Cetera Investment Advisers’ holdings in iShares Biotechnology ETF were worth $7,775,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Ramirez Asset Management Inc. purchased a new stake in shares of iShares Biotechnology ETF in the first quarter valued at $26,000. Berkshire Money Management Inc. acquired a new stake in iShares Biotechnology ETF in the 2nd quarter worth about $28,000. Harbor Asset Planning Inc. acquired a new stake in iShares Biotechnology ETF in the 2nd quarter worth about $31,000. Trust Co. of Toledo NA OH purchased a new stake in iShares Biotechnology ETF in the 2nd quarter valued at about $32,000. Finally, Security National Bank acquired a new position in shares of iShares Biotechnology ETF in the 2nd quarter valued at $38,000. Institutional investors and hedge funds own 62.45% of the company’s stock.

iShares Biotechnology ETF Price Performance

Shares of NASDAQ IBB opened at $167.52 on Friday. The firm has a fifty day moving average of $153.36 and a 200-day moving average of $138.48. iShares Biotechnology ETF has a 52-week low of $107.43 and a 52-week high of $168.73.

iShares Biotechnology ETF Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, September 19th. Shareholders of record on Tuesday, September 16th were paid a dividend of $0.0828 per share. The ex-dividend date was Tuesday, September 16th. This represents a $0.33 annualized dividend and a yield of 0.2%.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.